TACC2 and gastric cancer: To figure out the role of TACC2-FGFR2 fusion in targeted therapy for GC, we treated MKN45, NUGC4 cells and TACC2-FGFR2-expressing MKN45, NUGC4 cells with FGFR2 inhibitors, including BGJ398, AZD4547 and Erdafitinib.